Viral proteins

Viracta Therapeutics to Present at the H.C. Wainwright 22nd Annual Global Investment Conference

Retrieved on: 
Wednesday, September 9, 2020
Infectious causes of cancer, Nasopharyngeal carcinoma, Pharynx, Clinical medicine, Medical specialties, Lymphoma, Epstein–Barr virus, Branches of biology, Epstein–Barr virus infection, Viral proteins

SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 3:00 pm ET.

Key Points: 
  • SAN DIEGO, Sept. 9, 2020 /PRNewswire/ -- Viracta Therapeutics, Inc. (the "Company"), a precision oncology company targeting virus-associated malignancies, today announced that Ivor Royston, MD, President and Chief Executive Officer of Viracta, will present a corporate overview at the H.C. Wainwright 22nd Annual Global Investment Conference on Tuesday, September 15, 2020 at 3:00 pm ET.
  • Viracta is a precision oncology company targeting virus-associated malignancies.
  • The Company's proprietary investigational drug, nanatinostat, is currently being evaluated in combination with the antiviral agent valganciclovir as an oral combination therapy in a Phase 2 clinical trial for EBV-positive lymphomas.
  • Viracta is pursuing application of this kick and kill approach in other EBV-associated malignancies, such as nasopharyngeal carcinoma and gastric carcinoma, and other viral-related cancers.

Relapsed/Refractory (R/R) Epstein-Barr Virus (EBV) 2020: Industry and Pipeline Assessment - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 2, 2020
Health, Pharmaceutical, Epstein–Barr virus, Infectious causes of cancer, Viral proteins, EBV, Lymphoma, Medical specialties, Clinical medicine, Health, Non-Hodgkin lymphoma, Epstein–Barr virus vaccine, Epstein–Barr virus-associated lymphoproliferative diseases

The "Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) - Pipeline Insight, 2020" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This report outlays comprehensive insights of present clinical development scenario and growth prospects across the Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) market.
  • A detailed picture of the Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) pipeline landscape is provided, which includes the disease overview and Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) treatment guidelines.
  • The assessment part of the report embraces in-depth Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) commercial assessment and clinical assessment of the Relapsed/Refractory (R/R) Epstein-Barr virus (EBV) pipeline products from the pre-clinical developmental phase to the marketed phase.

HKBU-led Research Team Develops Novel Anti-viral Targeted Drug for Nasopharyngeal Cancer Treatment

Retrieved on: 
Monday, May 11, 2020
Viral proteins, Epstein–Barr virus nuclear antigen 1

Our new drug represents the first specific targeted agent to disrupt a single viral protein and to potently reactivate EBV from its latency.

Key Points: 
  • Our new drug represents the first specific targeted agent to disrupt a single viral protein and to potently reactivate EBV from its latency.
  • The research team constructed a new peptide drug with higher affinity to the EBNA1 protein, leading to the disruption of the structure and functions of EBNA1.
  • The research team discovered that the new drug can reactivate EBV lytic cycle through the disruption of EBNA1, and provides a new mentality of treatment of NPC.
  • The research team tested the new drug in an animal model by injecting it into mice with heavy tumour burden of EBV-positive nasopharyngeal tumours.

HKBU-led Research Team Develops Novel Anti-viral Targeted Drug for Nasopharyngeal Cancer Treatment

Retrieved on: 
Monday, May 11, 2020
Viral proteins, Epstein–Barr virus nuclear antigen 1

Our new drug represents the first specific targeted agent to disrupt a single viral protein and to potently reactivate EBV from its latency.

Key Points: 
  • Our new drug represents the first specific targeted agent to disrupt a single viral protein and to potently reactivate EBV from its latency.
  • The research team constructed a new peptide drug with higher affinity to the EBNA1 protein, leading to the disruption of the structure and functions of EBNA1.
  • The research team discovered that the new drug can reactivate EBV lytic cycle through the disruption of EBNA1, and provides a new mentality of treatment of NPC.
  • The research team tested the new drug in an animal model by injecting it into mice with heavy tumour burden of EBV-positive nasopharyngeal tumours.

New Visualisation of Covid-19 Available From Fusion Medical Animation

Retrieved on: 
Wednesday, March 11, 2020
Branches of biology, Proteins, Hormones, Viral proteins, env, Membrane protein, Insulin

Therefore, using the latest research available, Fusion Medical Animation have been able to create a 3D visual and animation of covid-19.

Key Points: 
  • Therefore, using the latest research available, Fusion Medical Animation have been able to create a 3D visual and animation of covid-19.
  • This visual is available (for no charge) to anyone who might have a use for it.
  • Please credit Fusion Medical Animation.
  • For this overall representation surface protein density has been reduced to help show spike, envelope, and membrane proteins.

New Visualisation of Covid-19 Available From Fusion Medical Animation

Retrieved on: 
Wednesday, March 11, 2020
Branches of biology, Proteins, Hormones, Viral proteins, env, Membrane protein, Insulin

Therefore, using the latest research available, Fusion Medical Animation have been able to create a 3D visual and animation of covid-19.

Key Points: 
  • Therefore, using the latest research available, Fusion Medical Animation have been able to create a 3D visual and animation of covid-19.
  • This visual is available (for no charge) to anyone who might have a use for it.
  • Please credit Fusion Medical Animation.
  • For this overall representation surface protein density has been reduced to help show spike, envelope, and membrane proteins.

Glycoprotein 41, Pipeline Review, H2 2019 - Frontier Biotechnologies Inc, Mymetics Corp, Novodux & Protheragen Inc - ResearchAndMarkets.com

Retrieved on: 
Wednesday, January 22, 2020
Health, Pharmaceutical, HIV/AIDS, Viral proteins, Branches of biology, Glycoproteins, Gp41, VIR-576

The "Glycoprotein 41 (gp41) - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Glycoprotein 41 (gp41) - Pipeline Review, H2 2019" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • According to the recently published report 'Glycoprotein 41 (gp41) - Pipeline Review, H2 2019'; Glycoprotein 41 (gp41) pipeline Target constitutes close to 20 molecules.
  • Glycoprotein 41 (gp41) - Gp41 or glycoprotein 41 is a transmembrane protein that contains several sites within its ectodomain that are required for infection of host cells.
  • It also reviews key players involved in Glycoprotein 41 (gp41) targeted therapeutics development with respective active and dormant or discontinued projects.

ViiV Healthcare announces exclusive licensing agreement with the National Institutes of Health for investigational “bNAb” with potential for long-acting HIV treatment and prevention

Retrieved on: 
Thursday, November 21, 2019
Biotechnology, AIDS, Health, General Health, Pharmaceutical, Other Science, Research, Gay & Lesbian, Infectious diseases, Consumer, Science, Medical specialties, Branches of biology, HIV/AIDS, Medicine, Glycoproteins, Immunology, Viral proteins, Envelope glycoprotein GP120, Antibodies, HIV, CD4, T helper cell

Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells.

Key Points: 
  • Broadly neutralising antibodies are antibodies that can recognise and block the entry of different strains of HIV into healthy cells.
  • N6LS is an antiviral bNAb that works by binding to a specific site (gp120) on the surface of HIV that prevents its entry into uninfected immune system cells (CD4+ T-cells).
  • This exclusive license outlines a programme for ViiV Healthcares development of N6LS as well as milestone payments and royalties to the NIAID.
  • GSK is a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.

Viracta Announces Oral Presentation on Lead Program for EBV-associated Lymphomas at the 2019 American Society of Hematology (ASH) Annual Meeting

Retrieved on: 
Wednesday, November 6, 2019
Herpesviridae, Viruses, Medical specialties, Infectious causes of cancer, Viral proteins, Lymphoma, Epstein–Barr virus, Epstein–Barr virus infection, Epstein-Barr virus-associated lymphoproliferative diseases

The nanatinostat and valganciclovir combination in EBV-associated lymphomas is being investigated in an ongoing Phase 2 clinical trial.

Key Points: 
  • The nanatinostat and valganciclovir combination in EBV-associated lymphomas is being investigated in an ongoing Phase 2 clinical trial.
  • Approximately 95% of the world's adult population is infected with Epstein-Barr Virus (EBV), yet infections are commonly asymptomatic.
  • Following infection, the virus remains latent in a small subset of lymphatic cells for the duration of the patients' life.
  • The Company's proprietary lead molecule, nanatinostat, is currently being evaluated in combination with valganciclovir as an oral combination therapy in a Phase 2 clinical trial for Epstein-Barr virus positive lymphomas.

Immunomic Therapeutics to Present at the First International Symposium on Merkel Cell Carcinoma 2019

Retrieved on: 
Friday, October 18, 2019
Oncology, Health, Genetics, Clinical trials, Pharmaceutical, Biotechnology, Polyomaviridae, Cancer, Infectious causes of cancer, Medicine, Medical specialties, Viral proteins, Merkel cell polyomavirus, Merkel-cell carcinoma, Large tumor antigen, Vaccination, LAMP1, Tumor antigen, UNITE, Immunomic Therapeutics, Inc.

UNITE fuses a tumor-associated antigen, in this case a mutated form of the large T antigen (LT) of Merkel cell polyomavirus (MCPyV), with lysosomal-associated membrane protein 1 (LAMP1).

Key Points: 
  • UNITE fuses a tumor-associated antigen, in this case a mutated form of the large T antigen (LT) of Merkel cell polyomavirus (MCPyV), with lysosomal-associated membrane protein 1 (LAMP1).
  • The data will be presented at the First International Symposium on Merkel Cell Carcinoma in Tampa, Florida.
  • ITI-3000 is an innovative and novel targeted approach to a MCPyV vaccine, says Teri Heiland, Ph.D., Immunomics Chief Scientific Officer.
  • The majority of Merkel cell carcinomas (MCC) are associated with MCPyV infection, making LT an attractive target for therapeutic cancer vaccines.